These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32675194)

  • 1. Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer.
    Fujiwara K; Saung MT; Jing H; Herbst B; Zarecki M; Muth S; Wu A; Bigelow E; Chen L; Li K; Jurcak N; Blair AB; Ding D; Wichroski M; Blum J; Cheadle N; Koenitzer J; Zheng L
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32675194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
    Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
    Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
    Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
    J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma.
    Wang J; Saung MT; Li K; Fu J; Fujiwara K; Niu N; Muth S; Wang J; Xu Y; Rozich N; Zlomke H; Chen S; Espinoza B; Henderson M; Funes V; Herbst B; Ding D; Twyman-Saint Victor C; Zhao Q; Narang A; He J; Zheng L
    J Exp Med; 2022 May; 219(5):. PubMed ID: 35404390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.
    Blair AB; Kleponis J; Thomas DL; Muth ST; Murphy AG; Kim V; Zheng L
    J Clin Invest; 2019 Apr; 129(4):1742-1755. PubMed ID: 30747725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.
    Azad A; Yin Lim S; D'Costa Z; Jones K; Diana A; Sansom OJ; Kruger P; Liu S; McKenna WG; Dushek O; Muschel RJ; Fokas E
    EMBO Mol Med; 2017 Feb; 9(2):167-180. PubMed ID: 27932443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells.
    Osipov A; Blair AB; Liberto J; Wang J; Li K; Herbst B; Xu Y; Li S; Niu N; Rashid R; Ding D; Liu Y; Wang Z; Wolfgang CL; Burkhart RA; Laheru D; Zheng L
    Cancer Biol Med; 2021 Feb; 18(1):206-214. PubMed ID: 33628595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
    Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade.
    Lander VE; Belle JI; Kingston NL; Herndon JM; Hogg GD; Liu X; Kang LI; Knolhoff BL; Bogner SJ; Baer JM; Zuo C; Borcherding NC; Lander DP; Mpoy C; Scott J; Zahner M; Rogers BE; Schwarz JK; Kim H; DeNardo DG
    Cancer Discov; 2022 Dec; 12(12):2774-2799. PubMed ID: 36165893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
    Jhawar SR; Wang SJ; Thandoni A; Bommareddy PK; Newman JH; Marzo AL; Kuzel TM; Gupta V; Reiser J; Daniels P; Schiff D; Mitchell D; LeBoeuf NR; Simmons C; Goyal S; Lasfar A; Guevara-Patino JA; Haffty BG; Kaufman HL; Silk AW; Zloza A; Giurini EF
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review.
    Li HB; Yang ZH; Guo QQ
    Cell Commun Signal; 2021 Nov; 19(1):117. PubMed ID: 34819086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC.
    Olaoba OT; Ligali FC; Alabi ZO; Akinyemi AO; Ayinde KS
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188483. PubMed ID: 33232723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
    Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
    Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
    [No Abstract]   [Full Text] [Related]  

  • 19. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
    Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
    Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies.
    Li X; Xiao C; Li R; Zhang P; Yang H; Cao D
    Front Immunol; 2024; 15():1326556. PubMed ID: 38415262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.